Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Total Liabilities (2019 - 2025)

Cellebrite DI's Total Liabilities history spans 7 years, with the latest figure at $454.5 million for Q4 2025.

  • Quarterly Total Liabilities rose 28.2% to $454.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $454.5 million through Dec 2025, up 28.2% year-over-year, with the annual reading at $454.5 million for FY2025, 28.2% up from the prior year.
  • Total Liabilities came in at $454.5 million for Q4 2025, up from $386.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $596.7 million in Q2 2024 to a low of $293.0 million in Q3 2022.
  • The 5-year median for Total Liabilities is $382.8 million (2025), against an average of $402.4 million.
  • Year-over-year, Total Liabilities soared 107.21% in 2021 and then plummeted 37.68% in 2025.
  • Cellebrite DI's Total Liabilities stood at $413.1 million in 2021, then dropped by 20.26% to $329.4 million in 2022, then surged by 51.38% to $498.7 million in 2023, then dropped by 28.9% to $354.5 million in 2024, then grew by 28.2% to $454.5 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Total Liabilities are $454.5 million (Q4 2025), $386.6 million (Q3 2025), and $379.0 million (Q2 2025).